Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

2 May 2023

Abstract excerpt

Despite negative results of clinical trials conducted on the overall population of patients with gastric cancer, PARP inhibitor (PARPi) therapeutic strategy still might represent a window of opportunity for a subpopulation of patients with gastric cancer. An estimated 7% to 12% of gastric cancers exhibit a mutational signature associated with homologous recombination (HR) failure, suggesting that these patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Gastric Cancer Management and Outcomes
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37129948
DOI: 10.1158/0008-5472.can-22-2620

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP InhibitorsPMID 37129948Read ↗

A mutational signature in gastric cancer suggests therapeutic strategies.Semantic proximity Read ↗

Advancements and Obstacles of PARP Inhibitors in Gastric CancerSemantic proximity Read ↗

Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal CancersSemantic proximity Read ↗

Diagnostic tool to identify and treat DNA repair deficient gastroesophageal adenocarcinomasSemantic proximity Read ↗

Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical PerspectivesSemantic proximity Read ↗

Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibitionSemantic proximity Read ↗

Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for TherapySemantic proximity Read ↗

BReast CAncer (BRCA) gene mutations as an emerging biomarker for the treatment of gastrointestinal malignancies.Semantic proximity Read ↗

The prognostic and predictive value of homologous recombination deficiency in gastrointestinal cancerSemantic proximity Read ↗

Genomic Determinants of Homologous Recombination Deficiency across Human CancersSemantic proximity Read ↗

Targeting PARP-1 and DNA Damage Response Defects in Colorectal Cancer Chemotherapy with Established and Novel PARP InhibitorsSemantic proximity Read ↗

Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targetingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.